Patrick Haslett

Title: Patrick Haslett: Innovator in RNAi Therapeutics

Introduction

Patrick Haslett is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) agents. His work focuses on addressing critical health issues associated with amyloid precursor protein (APP) and related disorders.

Latest Patents

Patrick Haslett holds 1 patent for his invention titled "Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof." This patent discloses double-stranded ribonucleic acid (dsRNAi) agents and compositions that target the APP gene. The methods outlined in the patent aim to inhibit the expression of the APP gene and provide treatment options for subjects suffering from APP-associated diseases, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer disease (EOFAD or eFAD).

Career Highlights

Throughout his career, Patrick Haslett has worked with prominent companies in the biotechnology sector. He has been associated with Alnylam Pharmaceuticals, Inc. and Shire Human Genetic Therapies, Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Patrick Haslett has collaborated with esteemed colleagues in the field, including Stuart Milstein and Kirk Brown. These partnerships have further enhanced his research and development efforts in RNAi therapeutics.

Conclusion

Patrick Haslett is a distinguished inventor whose work in RNAi technology has the potential to transform treatment options for serious neurological conditions. His contributions to the field are invaluable, and his ongoing research continues to inspire advancements in biotechnology.